Drug Stability: ICH versus Accelerated Predictive Stability Studies.

Area of Science:

• Pharmaceutical Science
• Drug Development
• Regulatory Affairs

Background:

• International Council for Harmonisation (ICH) guidelines establish global standards for pharmaceutical stability testing.
• ICH stability studies assess drug substance thermal stability and moisture sensitivity under defined storage conditions.
• Conventional ICH stability testing is rigorous, time-consuming, and requires extensive preclinical data.

Purpose of the Study:

• To review and compare conventional ICH stability studies with Accelerated Predictive Stability (APS) approaches.
• To highlight the advantages and disadvantages of both stability testing strategies.
• To discuss stability requirements for industrially fabricated medicines versus extemporaneous compounding formulations.

Main Methods:

• Review of established ICH stability testing protocols (long-term, intermediate, accelerated).
• Analysis of Accelerated Predictive Stability (APS) methodologies utilizing extreme conditions over shorter durations.
• Comparative assessment of data generation timelines and resource requirements for both methods.

Main Results:

• ICH stability studies involve long-term (≥12 months), intermediate (≥6 months), and accelerated (≥6 months) testing under specific temperature and humidity conditions.
• APS studies predict long-term stability in a significantly shorter timeframe (3-4 weeks) using extreme temperature and RH conditions.
• APS offers a more efficient alternative for predicting pharmaceutical product stability compared to conventional ICH methods.

Conclusions:

• APS presents a novel, efficient approach to predict long-term pharmaceutical stability, reducing time and resources.
• Understanding the differences between ICH and APS is crucial for optimizing drug development timelines.
• Stability requirements differ significantly between mass-produced medicines and compounded formulations.